Preferred Label : quinazolinones;
MeSH definition : Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one
of the carbons oxidized with a keto oxygen.;
MeSH synonym : Quinazolinone;
MeSH hyponym : quinazolinediones; Quinazolinedione;
Wikipedia link : https://en.wikipedia.org/wiki/Quinazolinones;
Is substance : O;
Origin ID : D052999;
UMLS CUI : C1720912;
Allowable qualifiers
Record concept(s)
Related MeSH Supplementary Concept(s)
- AJM300 [MeSH Supplementary Concept]
- ATF936 [MeSH Supplementary Concept]
- ATH434 [MeSH Supplementary Concept]
- AXT914 [MeSH Supplementary Concept]
- CAL-130 [MeSH Supplementary Concept]
- DPC 961 [MeSH Supplementary Concept]
- GS-9829 [MeSH Supplementary Concept]
- GT 28 [MeSH Supplementary Concept]
- HQ-275 [MeSH Supplementary Concept]
- HQ-355 [MeSH Supplementary Concept]
- IMB-170 [MeSH Supplementary Concept]
- MC 2141 [MeSH Supplementary Concept]
- MCI 176 [MeSH Supplementary Concept]
- ME0328 [MeSH Supplementary Concept]
- MK-0249 [MeSH Supplementary Concept]
- NO 794 [MeSH Supplementary Concept]
- R 59949 [MeSH Supplementary Concept]
- RVX-297 [MeSH Supplementary Concept]
- SL-512 [MeSH Supplementary Concept]
- U-29409 [MeSH Supplementary Concept]
- YIL 781 [MeSH Supplementary Concept]
- YIL 870 [MeSH Supplementary Concept]
- Zj6413 [MeSH Supplementary Concept]
- savirin [MeSH Supplementary Concept]
Semantic type(s)
Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one
of the carbons oxidized with a keto oxygen.
https://www.has-sante.fr/jcms/p_3119789/fr/vizimpro
2019
false
false
false
France
dacomitinib
administration, oral
treatment outcome
antineoplastic agents
protein kinase inhibitors
insurance, health, reimbursement
adult
neoplasm metastasis
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Product containing precisely dacomitinib 45 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely dacomitinib 30 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely dacomitinib 15 milligram/1 each conventional release
oral tablet (clinical drug)
evaluation of the transparency committee
dacomitinib
quinazolinones
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
dacomitinib
antineoplastic agents
antineoplastic agents
adult
carcinoma, non-small-cell lung
neoplasm metastasis
Advanced Malignant Neoplasm
ErbB Receptors
carcinoma, non-small-cell lung
administration, oral
product surveillance, postmarketing
protein kinase inhibitors
protein kinase inhibitors
aged
drug interactions
pregnancy
breast feeding
EGFR protein, human
Progression-Free Survival
drug evaluation, preclinical
Product containing precisely dacomitinib 15 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely dacomitinib 30 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely dacomitinib 45 milligram/1 each conventional release
oral tablet (clinical drug)
Tyrosine Kinase Inhibitors
dacomitinib
dacomitinib
ErbB Receptors
quinazolinones
quinazolinones
---
https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig-idelalisib-antineoplasique
https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig
2018
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
Rituximab
continuity of patient care
pneumonia, pneumocystis
neutropenia
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---
Summary Safety Review - Zydelig (idelalisib) - Assessing the potential risk of serious
infections
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/zydelig-fra.php
2017
false
false
false
Canada
French
English
idelalisib
idelalisib
canada
administration, oral
antineoplastic agents
risk assessment
drug evaluation
Infections
Infections
pharmacovigilance note
purines
quinazolinones
---
http://www.has-sante.fr/portail/jcms/c_2628549/fr/zydelig
2016
false
false
false
France
French
treatment outcome
purines
quinazolinones
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
evaluation of the transparency committee
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
chromosome 17 deletion
phosphatidylinositol 3-Kinases
Smith-Magenis syndrome
chromosome deletion
chromosomes, human, pair 17
Phosphoinositide-3 Kinase Inhibitors
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/57590a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
canada
antineoplastic combined chemotherapy protocols
antineoplastic agents
idelalisib
early termination of clinical trials
idelalisib
purines
quinazolinones
---
ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58118a-fra.php
2016
false
false
false
Canada
French
English
survival analysis
idelalisib
idelalisib
leukemia, lymphocytic, chronic, B-Cell
risk assessment
antineoplastic agents
cause of death
Infections
antineoplastic combined chemotherapy protocols
Rituximab
continuity of patient care
pneumonia, pneumocystis
sepsis
cytomegalovirus infections
Chemotherapy-Induced febrile neutropenia
pharmacovigilance note
lymphoma, Non-Hodgkin
Indolent Non-Hodgkin Lymphoma
purines
quinazolinones
---
http://www.has-sante.fr/portail/jcms/c_2047021/fr/zydelig-idelalisib-inhibiteur-de-kinase
2015
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---
https://www.ema.europa.eu/medicines/human/EPAR/Zydelig
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
purines
purines
quinazolinones
quinazolinones
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
tablets
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
drug interactions
pregnancy
breast feeding
idelalisib
drug evaluation, preclinical
idelalisib
idelalisib
Idelalisib/Rituximab Regimen
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---